ConvaTec Group PLC John McAdam appointed Chairman of ConvaTec (4098J)
19 Agosto 2019 - 8:00AM
UK Regulatory
TIDMCTEC
RNS Number : 4098J
ConvaTec Group PLC
19 August 2019
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES
OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014
John McAdam appointed Chairman of ConvaTec
Reading, United Kingdom (19 August 2019): ConvaTec Group Plc
("ConvaTec" or "the Company") today is delighted to announce that
Dr John McAdam has been appointed Chairman of the Board of ConvaTec
with effect from 30(th) September 2019, the same date as Karim
Bitar joins as Chief Executive Officer of the Company.
John has recently stepped down as Chairman of Rentokil Initial
plc and is due to retire as Chairman of United Utilities Group PLC
on 31(st) December 2019, having taken up the role of Chairman of
both companies in 2008. He is also Senior Independent Director of
Cobham plc, a position he has held since August 2017, and a Non
Executive Director of Wilmcote Holdings plc since October 2018.
John has previously been a Non Executive Director of a number of
FTSE 100 and US companies, including Rolls-Royce Group plc, J
Sainsbury plc and The Sara Lee Corporation. He spent more than two
decades at Unilever before joining ICI, where he became Chief
Executive in 2003 until its takeover by Akzo Nobel in 2008.
With 20 years' service as a board director, including as
Chairman and Chief Executive Officer in companies undertaking
transformation, John has a wealth of experience on which to draw in
his role as Chairman and leader of the Board.
On 30(th) September, Rick Anderson will step down from his
current interim role as Executive Chairman to resume his role as a
Non Executive Director of ConvaTec.
Rick Anderson commented:
"I am delighted that John has agreed to become Chairman of the
Board of ConvaTec. He brings a wealth of experience to our Company,
as a senior executive, as Chairman and as a Board member of a
number of leading UK companies. John brings significant
transformational leadership to the Board, which will further enable
the acceleration of the Transformation Initiative that we launched
earlier this year. I am looking forward to working with John and
Karim Bitar to realise the full potential of the Group"
John McAdam added:
"ConvaTec has faced a number of challenges since its listing in
2016. The management team is already taking significant actions to
improve the Company's performance and I look forward to working
with Karim and the Board to continue the execution of the
transformation initiative and to deliver improved returns to our
shareholders. I would also like to acknowledge and thank Rick for
stepping forward in October 2018 to lead the Group during its
transition to a new leadership team. During this period, he has set
the Group on an important and new trajectory of execution and
change, including cultural change. This is a critical and valuable
base from which Karim and I will commence our tenure with the Group
and we and our shareholders will benefit greatly from Rick's
ongoing contribution to the Board, the Company and its
transformation."
Ends
Notes:
1. Dr McAdam will become Chairman of the Company's Nominations
Committee, with effect from his appointment as Chairman of the
Board.
2. This announcement is made in accordance with Listing Rule 9.6.11R (1).
3. In accordance with Listing Rule 9.6.13(1), Dr McAdam has
confirmed that he is currently a Director of United Utilities Group
PLC, Cobham plc and Wilmcote Holdings plc. He was a Director of
Rentokil Initial plc from 14 May 2008 to 8 May 2019 and of J
Sainsbury plc from 1 September 2005 to 6 July 2016.
4. In accordance with Listing Rule 9.6 13 (2) - (6) Dr McAdam
has advised that he has no details to disclose.
Enquiries:
Analysts and Investors
John Crosse, VP Investor Relations +44 (0)7500 141435
Mark Reynolds, Director Investor
Relations
investorrelations@convatec.com +44 (0)7551 036625
Media
Bobby Leach, VP Group Corporate
Affairs +44 (0)7770 842226
Finsbury
mediarelations@convatec.com +44 (0)207 2513801
About ConvaTec
ConvaTec is a global medical products and technologies company
focused on therapies for the management of chronic conditions, with
leading market positions in advanced wound care, ostomy care,
continence and critical care, and infusion devices. ConvaTec's
products provide a range of clinical and economic benefits
including infection prevention, protection of at-risk skin,
improved patient outcomes and reduced total cost of care. To learn
more about ConvaTec, please visit www.convatecgroup.com where a
copy of this announcement can also be found.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOAUWABRKAAWAAR
(END) Dow Jones Newswires
August 19, 2019 02:00 ET (06:00 GMT)
Grafico Azioni Convatec (LSE:CTEC)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Convatec (LSE:CTEC)
Storico
Da Apr 2023 a Apr 2024